Showing results (121-130 of 184) with videos related to
Sort By:
Pageof 19
Annals of Neurology|November 30, 2005
Prion protein codon 129 genotype prevalence is altered in primary progressive aphasiaXiaohong Li, Lewis P Rowland, Hiroshi Mitsumoto, et al.Arthritis & Rheumatology (Hoboken, N.J.)|February 28, 2014
Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositisRohit Aggarwal, Andriy Bandos, Ann M Reed, et al.Clinical and Experimental Rheumatology|February 28, 2025
Quantitative muscle magnetic resonance imaging as a biomarker for inclusion body myositis in clinical trials: exploring the in vivo effects of arimoclomolSharfaraz Salam, Jasper M Morrow, Michael P McDermott, et al.Journal of the Neurological Sciences|March 4, 2008
A novel tRNA(Val) mitochondrial DNA mutation causing MELASKurenai Tanji, Petra Kaufmann, Ali B Naini, et al.Muscle & Nerve|March 21, 2013
A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravisJames F Howard, Richard J Barohn, Gary R Cutter, et al.JAMA Neurology|June 26, 2013
High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trialRichard A Lewis, Michael P McDermott, David N Herrmann, et al.The Lancet. Neurology|October 26, 2017
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre studyJames F Howard, Kimiaki Utsugisawa, Michael Benatar, et al.Muscle & Nerve|October 4, 2002
Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravisGil I Wolfe, Richard J Barohn, Barbara M Foster, et al.Journal of Clinical Neuromuscular Disease|August 23, 2013
Leg amyotrophic diplegia: prevalence and pattern of weakness at US neuromuscular centersMazen M Dimachkie, Iryna M Muzyka, Jonathan S Katz, et al.Muscle & Nerve|June 2, 2021
Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patientsCarol Milligan, Nazem Atassi, Suma Babu, et al.Pageof 19